for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Synairgen plc

SYNG.L

Latest Trade

209.00GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

95.40

 - 

223.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
209.00
Open
--
Volume
--
3M AVG Volume
40.20
Today's High
--
Today's Low
--
52 Week High
223.80
52 Week Low
95.40
Shares Out (MIL)
201.34
Market Cap (MIL)
392.62
Forward P/E
-7.08
Dividend (Yield %)
--

Next Event

Full Year 2021 Synairgen PLC Earnings Release

Latest Developments

More

Synairgen Reports Preliminary Results For The Year Ended December 31

Synairgen FY Loss After Tax Widens

Synairgen Says Starts Dosing In Phase III Study Of Inhaled Interferon Beta In COVID-19 Patients

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Synairgen plc

Synairgen plc is a drug discovery and development company. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The Company is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The Company is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The Company offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

Industry

Biotechnology & Drugs

Contact Info

Southampton General Hosp, Tremona Road

SO16 6YD

United Kingdom

+44.23.80512800

http://www.synairgen.com/

Executive Leadership

Simon James Blouet Shaw

Non-Executive Chairman of the Board

John Ward

Chief Financial Officer, Executive Director

Phillip Monk

Chief Scientific Officer, Executive Director

Richard James Marsden

Chief Executive Officer, Executive Director

Gareth Walters

Chief Regulatory Officer

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (GBp)

2018

-3.449

2019

-3.529

2020

-9.460

2021(E)

-27.550
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.15
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-31.80
Return on Equity (TTM)
-30.05

Latest News

Latest News

Synairgen soars after drug shows promise in COVID-19 cases

Synairgen <SYNG.L> shares rose almost sixfold on Monday after the drugmaker said its medicine helped reduce the risk of severe cases in hospitalised patients with COVID-19, but some experts have cautioned against too much optimism in the market.

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.

BRIEF-Synairgen Announces Expansion Of Placebo-Controlled Home Setting Clinical Trial Of Sng001 In Patients With COVID-19

* SYNAIRGEN PLC - ANNOUNCES EXPANSION OF PLACEBO-CONTROLLED HOME SETTING CLINICAL TRIAL OF SNG001 IN PATIENTS WITH COVID-19

BRIEF-Synairgen Completes Recruitment Of 100 Patients In Clinical Trial Of SNG001 In COVID-19 Patients

* SYNAIRGEN - RECRUITMENT OF 100 HOSPITALISED PATIENTS IN CLINICAL TRIAL OF SNG001 IN COVID-19 PATIENTS COMPLETED Source text for Eikon: Further company coverage:

BRIEF-Synairgen Launches Expansion Of SG016 Trial Of SNG001 In COVID-19 Patients

* SYNAIRGEN PLC- HAS LAUNCHED EXPANSION OF SG016 TRIAL OF SNG001 IN COVID-19 PATIENTS TO DOSE PATIENTS IN HOME SETTING Source text for Eikon: Further company coverage:

BRIEF-Synairgen Pauses SG015 Trial Of SNG001 In COPD Patients

* SYNAIRGEN PLC - PAUSED SG015 TRIAL OF SNG001 IN COPD PATIENTS

BRIEF-Synairgen Says Approval Received To Extend Sg016 Clinical Study Of Sng001 In Covid-19

* SYNAIRGEN PLC - APPROVAL RECEIVED TO EXTEND SG016 CLINICAL STUDY OF SNG001 IN COVID-19 TO INITIATE PATIENTS IN HOME ENVIRONMENT Source text for Eikon: Further company coverage:

BRIEF-Synairgen Commences Dosing Patients In Trial Of Sng001 In Covid-19 Patients

* SYNAIRGEN PLC - COMMENCED DOSING PATIENTS IN ITS TRIAL OF SNG001 IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:

Synairgen gets green light for coronavirus drug trial

British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight against the pandemic.

BRIEF-Synairgen To Start Trial Of SNG01 In COVID-19

* GOT APPROVALS FROM MHRA AND HRA TO CONDUCT A TRIAL OF SNG001 (INHALED FORMULATION OF INTERFERON-BETA-1A) IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up